['hepatitis c']
['dcv/asv/bms-791325', 'ribavirin', 'sofosbuvir', 'peginterferon α-2a']

        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com.

        Inclusion Criteria:

          -  Males and Females ≥18 years of age, inclusive

          -  Chronic HCV infection Genotype 1 only

          -  Non-cirrhotic

          -  Treatment naive subjects with no previous exposure to an Interferon formulation (ie,
             IFNα, pegIFNα), ribavirin (RBV) or HCV Direct Acting Antiviral (DAA) (protease,
             polymerase inhibitor, etc.)

        Exclusion Criteria:

          -  HCV Genotype other than Genotype 1

          -  Documented or suspected hepatocellular carcinoma

          -  Evidence of decompensated liver disease

          -  Contraindication(s) to Peg/RBV therapy
      